During all three treatment cycles, the safety profile of ARIKACE was comparable to TOBI, with adverse events consistent with those seen in similar studies and expected in a population of CF patients receiving inhaled antibiotics. There was no difference between arms in the reporting of serious adverse events and there were no unexpected adverse events.
Fud - although premature and the biggest story will be in details, congrats to you. You have been on this board posting a lot of information to help new investors wade through all the spin. Again, thx and congrats
Apologies for taking so long to reply. I really appreciate that.
All I would add is that we tend to fear that other shareholders are simpletons who have no real idea of the inherent value of our investment. But I seriously wonder who is going to supply the shares needed by the investors who will build positions now that it's obvious the investment carries negligible risk.
One assumes whoever supplied four or five million shares to the tracker funds knew how the Phase III results were likely to be interpreted. But several million shares were removed from weak hands yesterday, and I suspect there's still a Short position to be covered in excess of two million shares.
Seems to me that between now and the end of this year the demand is likely to be far higher than the supply.